Ad is loading...
DNLI
Price
$24.69
Change
+$0.47 (+1.94%)
Updated
Nov 22 closing price
99 days until earnings call
NTLA
Price
$14.30
Change
+$0.50 (+3.62%)
Updated
Nov 22 closing price
88 days until earnings call
Ad is loading...

DNLI vs NTLA

Header iconDNLI vs NTLA Comparison
Open Charts DNLI vs NTLABanner chart's image
Denali Therapeutics
Price$24.69
Change+$0.47 (+1.94%)
Volume$830.36K
CapitalizationN/A
Intellia Therapeutics
Price$14.30
Change+$0.50 (+3.62%)
Volume$2.41M
CapitalizationN/A
DNLI vs NTLA Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
DNLI vs. NTLA commentary
Nov 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongSell and NTLA is a Hold.

COMPARISON
Comparison
Nov 25, 2024
Stock price -- (DNLI: $24.69 vs. NTLA: $14.30)
Brand notoriety: DNLI and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 101% vs. NTLA: 94%
Market capitalization -- DNLI: $3.55B vs. NTLA: $1.46B
DNLI [@Biotechnology] is valued at $3.55B. NTLA’s [@Biotechnology] market capitalization is $1.46B. The market cap for tickers in the [@Biotechnology] industry ranges from $468.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both DNLI and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 7 bearish.
  • NTLA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -1.44% price change this week, while NTLA (@Biotechnology) price change was +2.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 03, 2025.

NTLA is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.55B) has a higher market cap than NTLA($1.46B). DNLI YTD gains are higher at: 15.051 vs. NTLA (-53.099). DNLI has higher annual earnings (EBITDA): -496.05M vs. NTLA (-527.52M). DNLI has more cash in the bank: 837M vs. NTLA (658M). DNLI has less debt than NTLA: DNLI (52.5M) vs NTLA (102M). NTLA has higher revenues than DNLI: NTLA (43.1M) vs DNLI (0).
DNLINTLADNLI / NTLA
Capitalization3.55B1.46B244%
EBITDA-496.05M-527.52M94%
Gain YTD15.051-53.099-28%
P/E RatioN/AN/A-
Revenue043.1M-
Total Cash837M658M127%
Total Debt52.5M102M51%
FUNDAMENTALS RATINGS
DNLI vs NTLA: Fundamental Ratings
DNLI
NTLA
OUTLOOK RATING
1..100
6762
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
33
Fair valued
PROFIT vs RISK RATING
1..100
8597
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
4892
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a33

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (33) in the Biotechnology industry is somewhat better than the same rating for DNLI (93). This means that NTLA’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as NTLA (97). This means that DNLI’s stock grew similarly to NTLA’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as NTLA (97). This means that DNLI’s stock grew similarly to NTLA’s over the last 12 months.

DNLI's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for NTLA (92). This means that DNLI’s stock grew somewhat faster than NTLA’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as NTLA (100). This means that DNLI’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLINTLA
RSI
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
78%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VVIAX70.260.54
+0.77%
Vanguard Value Index Adm
AIWEX15.680.11
+0.71%
Cavanal Hill World Energy Institutional
CAMWX30.570.18
+0.59%
Cambiar Opportunity Inst
WCEAX19.690.06
+0.31%
Delaware Ivy Core Equity Fund Class A
GGCCX93.17-0.19
-0.20%
Gabelli Growth C

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.94%
BEAM - DNLI
63%
Loosely correlated
+6.23%
ALEC - DNLI
57%
Loosely correlated
+4.79%
JANX - DNLI
55%
Loosely correlated
+8.19%
LGND - DNLI
54%
Loosely correlated
+2.27%
NTLA - DNLI
54%
Loosely correlated
+3.62%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+3.62%
VCYT - NTLA
69%
Closely correlated
+1.67%
EDIT - NTLA
68%
Closely correlated
+2.95%
BEAM - NTLA
66%
Loosely correlated
+6.23%
CRSP - NTLA
63%
Loosely correlated
+3.43%
PRME - NTLA
58%
Loosely correlated
+7.74%
More